Krystal Biotech Inc
NASDAQ:KRYS
Krystal Biotech Inc
Cash from Financing Activities
Krystal Biotech Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Krystal Biotech Inc
NASDAQ:KRYS
|
Cash from Financing Activities
$202.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Krystal Biotech Inc's Cash from Financing Activities?
Cash from Financing Activities
202.8m
USD
Based on the financial report for Dec 31, 2023, Krystal Biotech Inc's Cash from Financing Activities amounts to 202.8m USD.
What is Krystal Biotech Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
22%
Over the last year, the Cash from Financing Activities growth was 474%. The average annual Cash from Financing Activities growth rates for Krystal Biotech Inc have been 20% over the past three years , 22% over the past five years .